Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MACROGENICS, INC.

(MGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MACROGENICS INC : Other Events, Financial Statements and Exhibits (form 8-K)

09/16/2021 | 04:07pm EST

Item 8.01 Other Events.

On September 16, 2021, MacroGenics, Inc. (the "Company") issued a press release announcing clinical results from Cohort A Part 1 of the Phase 2/3 MAHOGANY study of margetuximab in combination with retifanlimab in gastroesophageal adenocarcinoma (the "MAHOGANY Study Press Release"). In addition, on September 16, 2021, the Company also issued a press release announcing preliminary clinical results from the Phase 1 cohort expansion of the ongoing MGC018 study (the "MGC018 Study Press Release"). Copies of the MAHOGANY Study Press Release and MGC018 Study Press Release are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.


                   Item 9.01   Financial Statements and Exhibits


                                   (d)  Exhibits.


Exhibit Number                Description of Exhibit
  99.1                          MAHOGANY Study Press Release, dated September 16, 2021
  99.2                          MGC018 Study Press Release, dated September 16, 2021
                              Cover Page Interactive Data (embedded within the Inline XBRL
104                           document)

© Edgar Online, source Glimpses

All news about MACROGENICS, INC.
11/17Guggenheim Assumes MacroGenics at Buy with $30 Price Target
MT
11/03MacroGenics to Participate in Upcoming Investor Conferences
GL
11/03Wedbush Trims MacroGenics' Price Target to $30 From $32, Keeps Outperform Rating
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
PU
11/02MACROGENICS : Q3 Earnings Snapshot
AQ
11/02MACROGENICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/02Earnings Flash (MGNX) MACROGENICS Posts Q3 Revenue $15.7M
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
AQ
11/02MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/26MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
AQ
More news
Analyst Recommendations on MACROGENICS, INC.
More recommendations
Financials (USD)
Sales 2021 84,7 M - -
Net income 2021 -194 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,05x
Yield 2021 -
Capitalization 1 005 M 1 005 M -
Capi. / Sales 2021 11,9x
Capi. / Sales 2022 8,18x
Nbr of Employees 370
Free-Float 93,9%
Chart MACROGENICS, INC.
Duration : Period :
MacroGenics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MACROGENICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 16,40 $
Average target price 36,78 $
Spread / Average Target 124%
EPS Revisions
Managers and Directors
Scott E. Koenig President, Chief Executive Officer & Director
James Karrels Chief Financial Officer, Secretary & Senior VP
Paulo F. Costa Chairman
Ezio Bonvini Chief Scientific Officer & Senior VP-Research
Stephen L. Eck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MACROGENICS, INC.-27.34%1 005
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819